Industry deals

top of page

Search

ImmPACT Bio USA Inc. Raises $18 Million In Series A Financing

ImmPACT Bio USA Inc. Raises $18 Million In Series A Financing

ImmPACT Bio USA Inc. Raises $18 Million In Series A Financing

agbiopro

Aug 19, 20200 min read

GentiBio Launches with $20 Million Seed Funding from Novartis and Others

GentiBio Launches with $20 Million Seed Funding from Novartis and Others

GentiBio Launches with $20 Million Seed Funding from Novartis and Others

agbiopro

Aug 19, 20200 min read

Kymera Therapeutics Unveils IPO Pitch for Protein Degradation

Kymera Therapeutics Unveils IPO Pitch for Protein Degradation

Kymera Therapeutics Unveils IPO Pitch for Protein Degradation

agbiopro

Aug 3, 20200 min read

Sanofi Pays Kymera $150M to Kick Off Protein Degrader Partnership

Sanofi Pays Kymera $150M to Kick Off Protein Degrader Partnership

Sanofi Pays Kymera $150M to Kick Off Protein Degrader Partnership

agbiopro

Aug 3, 20200 min read

C4 Therapeutics Adds $170M to Test Protein Degraders in the Clinic

C4 Therapeutics Adds $170M to Test Protein Degraders in the Clinic

C4 Therapeutics Adds $170M to Test Protein Degraders in the Clinic

agbiopro

Jun 30, 20200 min read

Cambridge biotech launches with $50M to target 'junk DNA'

Cambridge biotech launches with $50M to target 'junk DNA'

Cambridge biotech launches with $50M to target 'junk DNA'

agbiopro

Apr 29, 20200 min read

With $45M Nurix Deal, Gilead Enters Crowded Protein Degradation Field

With $45M Nurix Deal, Gilead Enters Crowded Protein Degradation Field

With $45M Nurix Deal, Gilead Enters Crowded Protein Degradation Field

agbiopro

Jun 20, 20190 min read

InFarm Joins Vertical Farming Pantheon With Titanic $100m Series B

InFarm Joins Vertical Farming Pantheon With Titanic $100m Series B

InFarm Joins Vertical Farming Pantheon With Titanic $100m Series B

agbiopro

Jun 18, 20190 min read

UK Immune Cell Therapy Biotech Founded with €40M Series A

UK Immune Cell Therapy Biotech Founded with €40M Series A

UK Immune Cell Therapy Biotech Founded with €40M Series A

Quell Therapeutics, a London-based biotech developing immune cell therapies to target transplant rejection and autoimmune and...

agbiopro

May 30, 20191 min read

Vertex pays Kymera $70M upfront to discover protein degradation drugs

Vertex pays Kymera $70M upfront to discover protein degradation drugs

Vertex pays Kymera $70M upfront to discover protein degradation drugs

agbiopro

May 18, 20190 min read

Servier launches U.S. cancer business with plans to double headcount in next 5 years

Servier launches U.S. cancer business with plans to double headcount in next 5 years

Servier launches U.S. cancer business with plans to double headcount in next 5 years

agbiopro

May 10, 20190 min read

Ninjacart Raises $89m from Tiger Global in India’s Largest-Ever Farm Tech Deal

Ninjacart Raises $89m from Tiger Global in India’s Largest-Ever Farm Tech Deal

Ninjacart Raises $89m from Tiger Global in India’s Largest-Ever Farm Tech Deal

agbiopro

May 2, 20190 min read

AbbVie hands Voyager a mega-billions gene therapy deal, with $310M in near-term cash

AbbVie hands Voyager a mega-billions gene therapy deal, with $310M in near-term cash

AbbVie hands Voyager a mega-billions gene therapy deal, with $310M in near-term cash

agbiopro

Apr 28, 20190 min read

AbbVie puts up $105M for Tizona's preclinical I/O drug

AbbVie puts up $105M for Tizona's preclinical I/O drug

AbbVie puts up $105M for Tizona's preclinical I/O drug

agbiopro

Apr 23, 20190 min read

The top 20 preclinical biotech deals ranked by cash upfront reveals 3 big players — and some major l

The top 20 preclinical biotech deals ranked by cash upfront reveals 3 big players — and some major l

The top 20 preclinical biotech deals ranked by cash upfront reveals 3 big players — and some major l

agbiopro

Apr 23, 20190 min read

A 1.2 Bilion Gene Therapy Deal

A 1.2 Bilion Gene Therapy Deal

A 1.2 Bilion Gene Therapy Deal

Less than a month after Thermo Fisher unveiled a $1.7 billion deal to swallow Brammer Bio — a company that does contract viral vector...

agbiopro

Apr 21, 20191 min read

The Bristol-Celgene merger is approved. Here are 8 challenges ahead

The Bristol-Celgene merger is approved. Here are 8 challenges ahead

The Bristol-Celgene merger is approved. Here are 8 challenges ahead

agbiopro

Apr 14, 20190 min read

bottom of page